Assessing Functional Quality of Single TILs for Correlative Immunotherapy Biomarkers

Learn how using Single-Cell PSI™ can help you reveal mechanism in the Tumor Microenvironment.

Your data is in safe hands: we'll never sell it to third parties and you may always unsubscribe. Privacy Policy.

Challenge: Checkpoint combination studies need TILs solutions

Recently, checkpoint inhibitor blockade therapy has rapidly advanced and is now established as a powerful way to manage various malignant tumors. Despite the promising outcomes, there are a significant number of patients who do not respond to these immunotherapies.

In this Application Note we:
  • Highlight the challenges in functional characterization of TILs in checkpoint and combination therapies
  • Describe the workflow for functional single-cell analysis from both solid tumor TILs as well as patient PBMC
  • Predict patient response to checkpoint therapy using PSI as a biomarker in solid tumor TILs, as well as correlate response from these solid tumor TILs with PSI from peripheral blood
2019-07-16T14:52:58+00:00